BioSpace News Archive

Increasing need for real-time health monitoring and increasing need for early detection of diseases are some key factors driving market revenue growth.

PacBio announced that it will hold its quarterly conference call to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022, at 5:00 pm Eastern Time.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the first quarter 2022, after the market close on Wednesday, April 27, 2022.

Personalis, Inc., a leader in advanced genomics for cancer, announced that it will release its first quarter 2022 financial results on Wednesday, May 4, 2022.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 10, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 second quarter ended March 31, 2022.

GENFIT announced that it published in the April 20, 2022 French legal announcements bulletin n°47 its convening notice that the Combined Shareholders Meeting will be held on May 25, 2022, at 10:00am, at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.

Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2022 ended April 3, 2022, after the market close on Wednesday, May 4, 2022.

Samsara Vision, today announced FDA approval to initiate a U.S.-based, PMA supplemental study to evaluate improvements in visual acuity and the safety of its SING IMT™ (Smaller-Incision New-Generation Implantable Miniature Telescope) in people living with late-stage AMD.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced data demonstrating that MN-166 (ibudilast) prevents metastasis in a uveal melanoma (UM) animal model was published in the journal Molecular Cancer Research.

GATC Health, a biotech company revolutionizing drug discovery and disease prediction using artificial intelligence and advanced multiomics, announced it has filed a patent application for an innovative new prodrug designed to safely cross the blood-brain barrier for cancer treatment.